First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Scagliotti "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer" J Clin Oncol (2008) 10.1200/jco.2007.15.0375

[3]

Bover "Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study" Lancet (2009) 10.1016/s0140-6736(09)61497-5

[4]

Paz-Ares Lancet Oncol (2012) 10.1016/s1470-2045(12)70063-3

[5]

Sharma "Epidermal growth factor receptor mutations in lung cancer" Nat Rev Cancer (2007) 10.1038/nrc2088

[6]

Lynch "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib" N Engl J Med (2004) 10.1056/nejmoa040938

[7]

Paez "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy" Science (2004) 10.1126/science.1099314

[8]

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al.

New England Journal of Medicine 2010 10.1056/nejmoa0909530

[9]

Zhou "Erlotinib versus chemotherapy as first-line treatment for patients with advancedEGFR, mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study" Lancet Oncol (2011) 10.1016/s1470-2045(11)70184-x

[10]

Sequist "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma withEGFR mutations" J Clin Oncol (2013) 10.1200/jco.2012.44.2806

[11]

Hu "Synthesis and biological evaluation of crown ether fused quinazoline analogues as potentEGFR inhibitors" Bioorg Med Chem Lett (2012) 10.1016/j.bmcl.2012.06.067

[12]

Shi "Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial" Lancet Oncol (2013) 10.1016/s1470-2045(13)70355-3

[13]

Hu "A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)" Lung Cancer (2014) 10.1016/j.lungcan.2014.08.014

[14]

Shi "A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)" J Thorac Onco (2014) 10.1097/jto.0000000000000033

[15]

Inoue "Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitiveEGFR gene mutations (NEJ002)" Ann Oncol (2013) 10.1093/annonc/mds214

[16]

Zhou "Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment ofEGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)" Ann Oncol (2015) 10.1093/annonc/mdv276

[17]

Hu "The efficacy and safety of icotinib in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a single-arm, multi-center, prospective study" PLoS One (2015) 10.1371/journal.pone.0142500

[18]

Zhang "Trial-based cost-utility analysis of icotinib versus gefitinib as second-line therapy for advanced non-small cell lung cancer in China" PLoS One (2016) 10.1371/journal.pone.0151846

[19]

Qian "Pharmacoeconomic evaluation of EGFR-TKIs in the treatment of advanced non-small cell lung cancer" Chin J Drug Eval (2013)

[20]

Liang "Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboringEGFR mutations" PLoS One (2014) 10.1371/journal.pone.0085245

Cited By

275

Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy

Hao-Zhe Long, Meng-Jie Fu · 2026

Bioorganic & Medicinal Chemistr...

Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997–2026)

Zucheng Xie, Ruyun Gao · 2026

Chinese Medical Journal

Advances in molecular pathology and therapy of non-small cell lung cancer

Qing Huang, Yuanxiang Li · 2025

Signal Transduction and Targeted Th...

Incidence and risk factors of drug‐induced liver injury

Xiaoyun Li, Jieting Tang · 2022

Liver International

Metrics

275

Citations

20

References

Details

Published: Oct 01, 2017
Vol/Issue: 28(10)
Pages: 2443-2450
License: View

Authors

The R. W. Johnson Pharmaceutical Research Institute, Route 202, P.O. Box 300, Raritan, NJ 08869; and The Scripps Research Institute, Department of Molecular and Experimental Medicine, 10550 N. Torrey Pines Road, NX-1, La Jolla, CA 92037

Vrije Universiteit Amsterdam

Glasgow Caledonian University, Glasgow, G4 0BA, UK

a Merck Research Laboratories , Rahway, New Jersey, USA

Chinese Academy of Sciences

Cite This Article

Y.K. Shi, L. Wang, B.H. Han, et al. (2017). First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Annals of Oncology, 28(10), 2443-2450. https://doi.org/10.1093/annonc/mdx359

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

You May Also Like